Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations.

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Cancer Research

• Publication date

  1993-06-15

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 8504413
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Differential expression of glial- and neuronal-associated antigens in human tumors of the central and peripheral nervous system

  2004cited by this paper
• Amplified genes in human gliomas.

  1993cited by this paper
• MDM2 gene amplification in metastatic osteosarcoma.

  1993cited by this paper
• Amplified genes in human gliomas.

  1993cited by this paper
• The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth

  1993cited by this paper
• Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors.

  1992cited by this paper
• Evidence for the involvement of a potential second tumor suppressor gene on chromosome 17 distinct from p53 in malignant astrocytomas.

  1992cited by this paper
• p53 mutations in human malignant gliomas: comparison of loss of heterozygosity with mutation frequency.

  1992cited by this paper
• The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation.

  1992cited by this paper
• p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma.

  1992cited by this paper
• p53 mutation and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression.

  1992cited by this paper
• Amplification of a gene encoding a p53-associated protein in human sarcomas

  1992influential reference
• p53 mutations in human cancers.

  1991cited by this paper
• Infrequent p53 gene mutations in medulloblastomas.

  1991cited by this paper
• The p53 tumour suppressor gene

  1991cited by this paper
• Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line.

  1991cited by this paper
• Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo.

  1991cited by this paper
• Deletion mapping in human renal cell carcinoma.

  1989cited by this paper
• A cytogenetic study of 53 human gliomas.

  1989cited by this paper
• Specific chromosomal abnormalities in malignant human gliomas.

  1988cited by this paper
• Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line

  1987cited by this paper
• Cytogenetics of Solid Tumors

  1986cited by this paper

• Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies

  2025cites this paper
• Machine Learning for Detecting and Analyzing Chromoanagenesis Events.

  2025cites this paper
• Discovery of Furopyrimidine‐Pyrazole Hybrid Compounds Targeting p53‐MDM2 Interaction as Anticancer Agents

  2025cites this paper
• Selective Cleaning Enhances Machine Learning Accuracy for Drug Repurposing: Multiscale Discovery of MDM2 Inhibitors

  2025cites this paper
• Scalable co-sequencing of RNA and DNA from individual nuclei

  2025cites this paper
• Key genes altered in glioblastoma based on bioinformatics (Review)

  2025cites this paper
• The role of lncRNAs in the interplay of signaling pathways and epigenetic mechanisms in glioma.

  2025cites this paper
• Crossroads of cell fate: miR-34-mediated regulation of apoptosis and autophagy in glioblastoma

  2025cites this paper
• Degrons: defining the rules of protein degradation

  2025cites this paper
• Metabolic Roles of HIF1, c-Myc, and p53 in Glioma Cells

  2024cites this paper
• Role of scaffold proteins in the heterogeneity of glioblastoma

  2024cites this paper
• The Role of Mesenchymal Reprogramming in Malignant Clonal Evolution and Intra-Tumoral Heterogeneity in Glioblastoma

  2024cites this paper
• Glioblastoma heterogeneity at single cell resolution

  2023cites this paper
• Novel sights on therapeutic, prognostic, and diagnostics aspects of non-coding RNAs in glioblastoma multiforme

  2023cites this paper
• Cellular senescence in glioma

  2023cites this paper
• Recent insights into nanoformulation delivery systems of flavonoids against glioblastoma

  2023cites this paper
• Current Opportunities for Targeting Dysregulated Neurodevelopmental Signaling Pathways in Glioblastoma

  2022cites this paper
• Mechanisms of Cell Cycle Arrest and Apoptosis in Glioblastoma

  2022cites this paper
• Temozolomide-Acquired Resistance Is Associated with Modulation of the Integrin Repertoire in Glioblastoma, Impact of α5β1 Integrin

  2022cites this paper
• The Next Frontier: Translational Development of Ubiquitination, SUMOylation, and NEDDylation in Cancer

  2022cites this paper
• Molecular targeted therapy: A new avenue in glioblastoma treatment.

  2022cites this paper
• Gene Amplification in Tumor Cells: Developed De Novo or Adopted from Stem Cells

  2022cites this paper
• Chromoanagenesis Landscape in 10,000 TCGA Patients

  2021cites this paper
• Gene expression-based biomarkers designating glioblastomas resistant to multiple treatment strategies

  2021influential citation
• Consequences of Mutations and Abnormal Expression of SMAD4 in Tumors and T Cells

  2021cites this paper
• More Than Just Cleaning: Ubiquitin-Mediated Proteolysis in Fungal Pathogenesis

  2021cites this paper
• lncRNA TRMP-S directs dual mechanisms to regulate p27-mediated cellular senescence

  2021cites this paper
• Fluorine-18 Labeling of the MDM2 Inhibitor RG7388 for PET Imaging: Chemistry and Preliminary Evaluation.

  2021cites this paper
• Feasibility of Developing Radiotracers for MDM2: Synthesis and Preliminary Evaluation of an 18F-Labeled Analogue of the MDM2 Inhibitor SP-141

  2021cites this paper
• Dying to Survive—The p53 Paradox

  2021cites this paper
• Glioblastoma-initiating cell heterogeneity generated by the cell-of-origin, genetic/epigenetic mutation and microenvironment.

  2021cites this paper
• A Glance of p53 Functions in Brain Development, Neural Stem Cells, and Brain Cancer

  2020influential citation
• DNA Associated with Circulating Exosomes as a Biomarker for Glioma

  2020cites this paper
• MicroRNA-585 inhibits human glioma cell proliferation by directly targeting MDM2

  2020cites this paper
• Targeted modulation of E3 ligases using engineered ubiquitin variants

  2020cites this paper
• The effects of common variants in MDM2 and GNRH2 genes on the risk and survival of osteosarcoma in Han populations from Northwest China

  2020cites this paper
• Whole-genome sequencing of glioblastoma reveals enrichment of non-coding constraint mutations in known and novel genes

  2020cites this paper
• Glioblastoma multiforme: novel therapeutic targets

  2020influential citation
• Potential roads for reaching the summit: an overview on target therapies for high-grade gliomas

  2020cites this paper
• Targeted Brain Tumor Therapy by Inhibiting the MDM2 Oncogene: In Vitro and In Vivo Antitumor Activity and Mechanism of Action

  2020cites this paper
• Glioblastoma Multiforme: An Overview of Emerging Therapeutic Targets

  2019cites this paper
• Signal transduction pathways and resistance to targeted therapies in glioma.

  2019cites this paper
• Targeted Therapies for the Treatment of Glioblastoma in Adults

  2019cites this paper
• Changing paradigms for targeted therapies against diffuse infiltrative gliomas: tackling a moving target

  2019cites this paper
• Role of Genetic and Epigenetic Alterations in Pathogenesis of Neuroblastoma

  2019cites this paper
• MDM2 and mitochondrial function: One complex intersection.

  2019cites this paper
• Mdm2-P53 Interaction Inhibitor with Cisplatin Enhances Apoptosis in Colon and Prostate Cancer Cells In-Vitro

  2019cites this paper
• MDM2 Integrates Cellular Respiration and Apoptotic Signaling through NDUFS1 and the Mitochondrial Network.

  2019cites this paper
• Exploration of Involved Key Genes and Signaling Diversity in Brain Tumors

  2018cites this paper
• Genetic and epigenetic contribution to astrocytic gliomas pathogenesis

  2018cites this paper
• A patent review of the ubiquitin ligase system: 2015–2018

  2018cites this paper
• Potent effect of the MDM2 inhibitor AMG232 on suppression of glioblastoma stem cells

  2018cites this paper
• Revealing determinants of two‐phase dynamics of P53 network under gamma irradiation based on a reduced 2D relaxation oscillator model

  2018cites this paper
• Glioblastoma targeted therapy: updated approaches from recent biological insights

  2017cites this paper
• Generation and Validation of Intracellular Ubiquitin Variant Inhibitors for USP7 and USP10.

  2017cites this paper
• High Expression of Pirh2 is Associated with Poor Prognosis in Glioma

  2017cites this paper
• Negative auto-regulators trap p53 in their web.

  2017cites this paper
• Metabolic Reprogramming in Glioma

  2017cites this paper
• Genetic and Cellular Complexity of Brain Tumors

  2017cites this paper
• Upregulation of Coxsackie Adenovirus Receptor Sensitizes Cisplatin-Resistant Lung Cancer Cells to CRAd-Induced Inhibition

  2017cites this paper
• Co-operative intra-protein structural response due to protein–protein complexation revealed through thermodynamic quantification: study of MDM2-p53 binding

  2017cites this paper
• Advances in Biology and Treatment of Glioblastoma

  2017cites this paper
• Recent Advances for Targeted Therapies in Glioblastoma

  2017cites this paper
• Degrons in cancer

  2017influential citation
• Targeting Aberrant Signaling Pathways

  2017cites this paper
• Cell Signaling Pathways in Brain Tumors

  2017cites this paper
• Molecular Genetics of Tumors of the CNS 19 19 From : Contemporary Cancer Research : Brain Tumors

  2017cites this paper
• Regulation of kidney development by the Mdm2/Mdm4–p53 axis

  2017cites this paper
• Molecular Genetics of Secondary Glioblastoma

  2017cites this paper
• Pathology and Molecular Pathology of Brain Cancer

  2017cites this paper
• Essential Roles of E3 Ubiquitin Ligases in p53 Regulation

  2017cites this paper
• Dual targeting of MDM2 with a novel small-molecule inhibitor overcomes TRAIL resistance in cancer.

  2016cites this paper
• Improved Antitumor Effect of Survivin Responsive Conditional ReplicationAdenovirus in Combination with Cisplatin in Lung Cancer

  2016cites this paper
• The Role of MDM2 Amplification and Overexpression in Tumorigenesis.

  2016cites this paper
• Murine double minute 2, a potential p53-independent regulator of liver cancer metastasis

  2016cites this paper
• Lysine methylation represses p53 activity in teratocarcinoma cancer cells

  2016cites this paper
• Regulation of the Mdm2-p53 signaling axis in the DNA damage response and tumorigenesis.

  2016cites this paper
• Energetic Landscape of MDM2-p53 Interactions by Computational Mutagenesis of the MDM2-p53 Interaction

  2016cites this paper
• A novel all-trans retinoic acid derivative 4-amino‑2‑trifluoromethyl-phenyl retinate inhibits the proliferation of human hepatocellular carcinoma HepG2 cells by inducing G0/G1 cell cycle arrest and apoptosis via upregulation of p53 and ASPP1 and downregulation of iASPP.

  2016cites this paper
• Zinc and zinc-containing biomolecules in childhood brain tumors

  2016cites this paper
• MDM2 (Murine Double Minute 2 homolog) bindet und inhibiert den Vitamin D Rezeptor

  2016cites this paper
• The Role of MDM2 Phosphorylation in P53 Responses to DNA Damage and Tumor Suppression: A Dissertation

  2016cites this paper
• FUNCTION AND MECHANISM OF ALKBH5 IN N6-METHYL-ADENOSINE RNA MODIFICATION IN GLIOBLASTOMA

  2016cites this paper
• MDM2 oligomers: antagonizers of the guardian of the genome

  2016cites this paper
• Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date

  2015cites this paper
• Mechanisms of Chromosomal Instability in Glioblastoma

  2015cites this paper
• SYNTHETIC LETHALITY OF CDK INHIBITION AND DOXORUBICIN IN TRIPLE-NEGATIVE BREAST CANCER REQUIRES P53 INACTIVATION

  2015cites this paper
• Mutations of the human interferon alpha-2b gene in brain tumor patients exposed to different environmental conditions

  2015cites this paper
• Identifikation von Resistenzmechanismen gegenüber EGFR-Tyrosinkinase Inhibitoren in EGFR-amplifizierten und EGFRvIII-positiven Glioblastomen

  2015cites this paper
• Primary Tumors of the Nervous System

  2015influential citation
• MDM2 binds and inhibits vitamin D receptor

  2015cites this paper
• Whole genome sequence analysis links chromothripsis to EGFR, MDM2, MDM4, and CDK4 amplification in glioblastoma

  2015cites this paper
• Dysregulated glycolysis as an oncogenic event

  2015cites this paper
• Prognostic significance of MDM2 gene expression in childhood neuroblastoma.

  2015cites this paper
• A Novel Interaction between TFII-I and Mdm2 with a Negative Effect on TFII-I Transcriptional Activity

  2015cites this paper
• Adult High-Grade (Diffuse) Glioma

  2015cites this paper
• Verification of gene expression profiles for colorectal cancer using 12 internet public microarray datasets.

  2014cites this paper
• Molecular, histopathological, and genomic variants of glioblastoma.

  2014cites this paper
• Emerging drugs and combination strategies for basal cell carcinoma

  2014cites this paper
• Inhibition of protein-peptide interactions by small molecules

  2014influential citation